KetoSwiss raises $4.8M in 2nd closing of its pre-series A round

KetoSwiss develops "brain fuels" as nutraceuticals (supplements) and pharmaceuticals for the therapy of migraine ("MigraKet"), which are productive and close to the root cause of migraine without adding intolerable side effects. Its lead product's active substance is an endogenous metabolite, a ketone body, which can be used by the brain as an alternative fuel to glucose when glucose utilization or transport is compromised. In later stages of development, KetoSwiss' portfolio can be extended to other neurological diseases characterized by metabolic dysfunction, such as Alzheimer's Disease (AD). more